Metastatic Hormone Sensitive Prostate Cancer (Novartis)

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with SoC, Versus SoC Alone, in Adult Male Patients With mHSPC, (Metastatic Hormone Sensitive Prostate Cancer), (PSMAddition).

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. Approximately 1126 patients will be randomized in this study.

Cohort: Tx. naïve or minimally treated w/LHRH (ADT), ECOG 0-2.

Learn more.